Jacqueline Corrigan-Curay selected as permanent director of FDA Office of Medical Policy at the Center for Drug Evaluation and Research

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

JACQUELINE CORRIGAN-CURAY was selected as the permanent director of the FDA Office of Medical Policy at the Center for Drug Evaluation and Research. Corrigan-Curay most recently served as a supervisory medical officer with the Immediate Office of the Director at NIH’s National Heart, Lung, and Blood Institute, where she worked on establishing a new trans-NHLBI...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

The California Institute for Regenerative Medicine, a state agency tasked with awarding billions of dollars of scientific funding for stem cell and gene therapy, has rescinded a controversial policy that was disrupting the flow of funding to cancer research.
NCI has emerged relatively unscathed in the president’s FY 2027 budget request that would slash $15.8 billion from HHS funding, cut NIH overall by about 10%, eliminate three NIH institutes and centers, and move the Institute for Environmental Health Sciences and its circa $1 billion budget out of NIH.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login